Pros and cons for fluorescent in situ hybridization, karyotyping and next generation sequencing for diagnosis and follow-up of multiple myeloma

1Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018; 32(12): 2604-2616.BolliNBianconGMoariiMGimondiSLiYdePhilippis Cet alAnalysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroupsLeukemia201832122604261610.1038/s41375-018-0037-9Search in Google Scholar

2Li S, Lim HH, Woo KS, Kim SH, Han JY. A retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: A single center study in Korea. Blood Res. 2016; 51(2): 122-126.LiSLimHHWooKSKimSHHanJYA retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: A single center study in KoreaBlood Res201651212212610.5045/br.2016.51.2.122Search in Google Scholar

3Rajkumar SV. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J He-matol. 2014; 89(10): 999-1009.RajkumarSVMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementAm J He-matol20148910999100910.1002/ajh.23810Search in Google Scholar

4Talley PJ, Chantry AD, Buckle CH. Genetics in myeloma: Genetic technologies and their application to screening approaches in myeloma. Br Med Bull. 2015; 113(1): 15-30.TalleyPJChantryADBuckleCHGenetics in myeloma: Genetic technologies and their application to screening approaches in myelomaBr Med Bull20151131153010.1093/bmb/ldu041Search in Google Scholar

5Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117(18): 4696-4700.MunshiNCAndersonKCBergsagelPLShaughnessyJPalumboADurieBet alConsensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2Blood2011117184696470010.1182/blood-2010-10-300970Search in Google Scholar

6Yellapantula V, Hultcrantz M, Rustad EH, Was-serman E, Londono D, Cimera R, et al. Comprehensive detection of recurring genomic abnormalities: A targeted sequencing approach for multiple myeloma. Blood Cancer J. 2019; 9(12): 101-109.YellapantulaVHultcrantzMRustadEHWas-sermanELondonoDCimeraRet alComprehensive detection of recurring genomic abnormalities: A targeted sequencing approach for multiple myelomaBlood Cancer J201991210110910.1038/s41408-019-0264-ySearch in Google Scholar

7Aydin C, Ulas T, Hangul C, Yucel OK, Iltar U, Salim O, et al. Conventional cytogenetics and interphase fluorescence in situ hybridization results in multiple myeloma: A Turkey laboratory analysis of 381 cases. Indian J Hematol Blood Transfus. 2020; 36(2): 284291. doi: 10. 1007/s12288-019-01215-5. Epub 2019 Oct 25.AydinCUlasTHangulCYucelOKIltarUSalimOet alConventional cytogenetics and interphase fluorescence in situ hybridization results in multiple myeloma: A Turkey laboratory analysis of 381 casesIndian J Hematol Blood Transfus202036228429110.1007/s12288-019-01215-5.Epub 2019 Oct 25Open DOISearch in Google Scholar

8Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res. 2004; 64(4): 1546-1558.FonsecaRBarlogieBBatailleRBastardCBergsagelPLChesiMet alGenetics and cytogenetics of multiple myeloma: A workshop reportCancer Res20046441546155810.1158/0008-5472.CAN-03-2876Search in Google Scholar

9McGowan-Jordan J, Simons A, Schmid M, editors. An International System for Human Cytogenomic Nomenclature (ISCN 2016). Basel, Switzerland: Karger, 2016.McGowan-JordanJSimonsASchmidMeditorsAn International System for Human Cytogenomic Nomenclature (ISCN 2016)Basel, SwitzerlandKarger201610.1159/isbn.978-3-318-06861-0Search in Google Scholar

10Romano A, Palumbo GA, Parrinello NL, Conti-cello C, Martello M, Terragna C. Minimal residual disease assessment within the bone marrow of multiple myeloma: A review of caveats, clinical significance and future perspectives. Front Oncol. 2019; 9(20): 699.RomanoAPalumboGAParrinelloNLConti-celloCMartelloMTerragnaCMinimal residual disease assessment within the bone marrow of multiple myeloma: A review of caveats, clinical significance and future perspectivesFront Oncol201992069910.3389/fonc.2019.00699Search in Google Scholar

11Richards S, Aziz N, Bale S, Bick D, Das S, GastierFoster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint concensus recommendation of the American College of Medical Genetics and Genomics and the Association of Molecular Pathology. Genet Med. 2015; 17(5): 405-424. doi: 10. 1038/gim. 2015.30.RichardsSAzizNBaleSBickDDasSGastierFosterJet alStandards and guidelines for the interpretation of sequence variants: A joint concensus recommendation of the American College of Medical Genetics and Genomics and the Association of Molecular PathologyGenet Med201517540542410.1038/gim.2015.30Open DOISearch in Google Scholar

12Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. Mayo Clin Proc. 2010; 85(6): 532-537.KapoorPFonsecaRRajkumarSVSinhaSGertzMAStewartAKet alEvidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapiesMayo Clin Proc201085653253710.4065/mcp.2009.0677Search in Google Scholar

13Saxe D, Seo EJ, Bergeron MB, Han JY. Recent advances in cytogenetic characterization of multiple myeloma. Int J Lab Hematol. 2019; 41(1): 5-14.SaxeDSeoEJBergeronMBHanJYRecent advances in cytogenetic characterization of multiple myelomaInt J Lab Hematol201941151410.1111/ijlh.12882Search in Google Scholar

14Kaufmann H, Ackermann J, Greinix H, Nösslinger T, Gisslinger H, Keck A, et al. Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features. Ann Oncol. 2003; 14(11): 1667-1672.KaufmannHAckermannJGreinixHNösslingerTGisslingerHKeckAet alBeneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic featuresAnn Oncol200314111667167210.1093/annonc/mdg454Search in Google Scholar

15Durak BA, Akay OM, Sungar G, Bademci G, Aslan V, Caferler J, et al. Conventional and molecular cytogenetic analyses in Turkish patients with multiple myeloma. Turk J Haematol. 2012; 29(2): 135-142.DurakBAAkayOMSungarGBademciGAslanVCaferlerJet alConventional and molecular cytogenetic analyses in Turkish patients with multiple myelomaTurk J Haematol201229213514210.5152/tjh.2011.42Search in Google Scholar